TY - JOUR T1 - Four-week forecasts of COVID-19 epidemic trajectories in South Africa, Chile, Peru and Brazil: a model evaluation JF - medRxiv DO - 10.1101/2021.09.06.21263151 SP - 2021.09.06.21263151 AU - Wim Delva AU - Emanuel M. Dominic AU - Roxanne Beauclair AU - Rachid Ouifki AU - Matthys Kroon AU - Heinrich Volmink AU - Elton Dorkin Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/12/2021.09.06.21263151.abstract N2 - Introduction From the beginning of the COVID-19 pandemic, epidemiological models have been used in a number of ways to aid governments and organizations in efficient planning of resources and decision making. These models have elucidated important epidemiological transmission parameters, in addition to making short-term projections.Methods We constructed a compartmental mathematical model for the transmission, detection and prevention of SARS-CoV-2 infections for regions where Anglo American has mining operations. We fitted the model to publicly available data and used it to make short-term projections. Finally, we evaluated how the model performed by comparing short-term projections to actual confirmed cases, retrospectively.Findings The average forecast errors for four-week-ahead projections ranged between 1% and 8% in all the countries and regions considered in this study. All but one region had more than 75% of the true values falling within the range of four-week-ahead projections. The quality of the projections improved with time as expected due to increased historical data.Conclusion Our model produced four-week forecasts with a sufficiently high level of accuracy to guide operational and strategic planning for business continuity and COVID-19 responses in Anglo American mining sites.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAnglo Operations and Anglo Corporate Services South Africa funded the work presented.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research involved no personal identifiable information, and only publicly available aggregate data of daily COVID-19 cases and COVID-19 related deaths was used. The research focuses on population-level epidemic projections with no direct clinical implications. For this reason, no IRB approval nor exemption was sought.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are publicly available. https://github.com/dsfsi/covid19za Marivate, V. & Combrink, H. M. Use of available data to inform the covid-19 outbreak in south africa: A case study. DataSci. J.19, 1-7 (2020). https://github.com/CSSEGISandData/COVID-19 Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track covid-19 in real time. The Lancet infectious diseases 20, 533-534 (2020). https://www.worldometers.info/coronavirus/ Worldometer covid-19 coronavirus pandemic (2020). ER -